Gyre Therapeutics (GYRE) Net Margin (2010 - 2026)

Gyre Therapeutics (GYRE) has reported Net Margin for 16 consecutive years, with 38.59% the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Margin fell 5083.0% year-over-year to 38.59%; the TTM figure through Mar 2026 stood at 5.44% (down 1264.0% YoY), while the FY2025 annual figure was 4.31%, down 712.0% from the prior year.
• Net Margin slipped to 38.59% in Q1 2026 per GYRE's latest filing, from 4.63% in the prior quarter.
• Across five years, Net Margin topped out at 27.72% in Q1 2024 and bottomed at 1830.73% in Q1 2022.
• Historically, Net Margin has averaged 145.09% across 5 years, with a median of 4.41% in 2024.
• On a YoY basis, Net Margin climbed as much as 183973 bps in 2023 and fell as far as 34259 bps in 2023.
• Gyre Therapeutics' Net Margin stood at 29.47% in 2022, then plunged by 1163 bps to 372.06% in 2023, then soared by 100 bps to 0.36% in 2024, then tumbled by 1204 bps to 4.63% in 2025, then slumped by 733 bps to 38.59% in 2026.
• Business Quant data shows GYRE's Net Margin at 38.59% in Q1 2026, 4.63% in Q4 2025, and 11.81% in Q3 2025.